[1] A.J. Czaja, Difficult treatment decisions in autoimmune hepatitis, World J. Gastroenterol. 16 (2010) 934e947.
[2] G. Xia, S. Wu, Y. Zhang, Anti-4-1BB monoclonal antibodies attenuate conca- navalin A-induced immune-mediated liver injury in mice, Exp. Ther. Med. 12 (2016) 1263e1268.
[3] Y. Kaneko, M. Harada, T. Kawano, M. Yamashita, Y. Shibata, F. Gejyo, et al., Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A- induced hepatitis, J. Exp. Med. 191 (2000) 105e114.
[4] H. Ito, M. Hoshi, H. Ohtaki, A. Taguchi, K. Ando, T. Ishikawa, et al., Ability of IDO to attenuate liver injury in alpha-galactosylceramide-induced hepatitis model, J. Immunol. 185 (2010) 4554e4560.
[5] H. Ito, N. Koide, F. Hassan, S. Islam, G. Tumurkhuu, I. Mori, et al., Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock, Lab. Invest. 86 (2006) 254e261.
[6] T. Kawai, S. Akira, Toll-like receptors and their crosstalk with other innate receptors in infection and immunity, Immunity 34 (2011) 637e650.
[7] H. Guo, J.B. Callaway, J.P. Ting, Inflammasomes: mechanism of action, role in disease, and therapeutics, Nat. Med. 21 (2015) 677e687.
[8] Y. Zhang, Y. Zheng, H. Li, NLRP3 inflammasome plays an important role in the pathogenesis of collagen-induced arthritis, Mediat. Inflamm. 2016 (2016), 9656270.
[9] A. Lu, H. Li, J. Niu, S. Wu, G. Xue, X. Yao, et al., Hyperactivation of the NLRP3 inflammasome in myeloid cells leads to severe organ damage in experimental lupus, J. Immunol. 198 (2017) 1119e1129.
[10] A. Kastbom, D. Verma, P. Eriksson, T. Skogh, G. Wingren, P. Soderkvist, Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project), Rheumatol. Oxf. 47 (2008) 415e417.
[11] C.A. Yang, S.T. Huang, B.L. Chiang, Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages, Rheumatol. Oxf. 54 (2015) 324e331.
[12] R.J. Mathews, J.I. Robinson, M. Battellino, C. Wong, J.C. Taylor, S. Eyre, et al., Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment, Ann. Rheum. Dis. 73 (2014) 1202e1210.
[13] H. Ito, K. Ando, T. Nakayama, M. Taniguchi, T. Ezaki, K. Saito, et al., Role of Valpha 14 NKT cells in the development of impaired liver regeneration in vivo, Hepatology 38 (2003) 1116e1124.
[14] D. Brough, N.J. Rothwell, Caspase-1-dependent processing of pro-interleukin- 1beta is cytosolic and precedes cell death, J. Cell Sci. 120 (2007) 772e781.
[15] M.T. Chow, J. Sceneay, C. Paget, C.S. Wong, H. Duret, J. Tschopp, et al., NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases, Cancer Res. 72 (2012) 5721e5732.
[16] E.N. Tsiganov, E.M. Verbina, T.V. Radaeva, V.V. Sosunov, G.A. Kosmiadi, I.Y. Nikitina, et al., Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice, J. Immunol. 192 (2014) 4718e4727.
[17] J.F. Camargo, P.A. Correa, J. Castiblanco, J.M. Anaya, Interleukin-1beta poly- morphisms in Colombian patients with autoimmune rheumatic diseases, Genes Immun. 5 (2004) 609e614.
[18] C.A. Yang, B.L. Chiang, Inflammasomes and human autoimmunity: a comprehensive review, J. Autoimmun. 61 (2015) 1e8.
[19] M. Shindo, G.E. Mullin, L. Braun-Elwert, N.V. Bergasa, E.A. Jones, S.P. James, Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB), Clin. Exp. Immunol. 105 (1996) 254e259.
[20] S. Satoh, A.K. Nussler, Z.Z. Liu, A.W. Thomson, Proinflammatory cytokines and endotoxin stimulate ICAM-1 gene expression and secretion by normal human hepatocytes, Immunology 82 (1994) 571e576.
[21] A. Ikeda, N. Aoki, M. Kido, S. Iwamoto, H. Nishiura, R. Maruoka, et al., Pro- gression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice, Hepatology 60 (2014) 224e236.
[22] S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, L.W. Moreland, et al., Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo- controlled trial, Arthritis Rheum. 46 (2002) 614e624.
[23] X. Le Loet, D. Nordstrom, M. Rodriguez, A. Rubbert, P. Sarzi-Puttini, J.M. Wouters, et al., Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA trial, J. Rheumatol. 35 (2008) 1538e1544.
[24] M.T. Chow, J. Tschopp, A. Moller, M.J. Smyth, NLRP3 promotes inflammation- induced skin cancer but is dispensable for asbestos-induced mesothelioma, Immunol. Cell Biol. 90 (2012) 983e986.
[25] B.H. Koehn, P. Apostolova, J.M. Haverkamp, J.S. Miller, V. McCullar, J. Tolar, et al., GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells, Blood 126 (2015) 1621e1628.
[26] A.J. Czaja, Diagnosis and management of autoimmune hepatitis: current status and future directions, Gut Liver 10 (2016) 177e203.